Latest Gene therapy Stories
- Hematologist and Gene Therapy Expert at The Children's Hospital of Philadelphia Joins an Elite Honorary Society - PHILADELPHIA, May 10, 2011 /PRNewswire-USNewswire/ -- Katherine A. High, M.D., a gene therapy expert at The Children's Hospital of Philadelphia, has been elected to the 2011 class of the American Academy of Arts and Sciences. The Academy is one of the nation's most prestigious honorary societies and is a leading center for independent policy research. Dr. High joins a select...
AMSTERDAM, May 10, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, provided today a status update on Glybera (alipogene tiparvovec), its gene therapy product under development for the treatment of lipoprotein lipase deficiency (LPLD). Following the submission of the Day 180 questions at the end of the first quarter to the European Medicines Agency (EMA) as part of Glybera's Market Authorisation...
Disorders of the eye are excellent targets for gene therapy because the ocular environment is readily accessible, relatively easy to monitor, and sequestered from the rest of the body. A series of articles available online ahead of print in Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com), highlight several exciting developments in ocular gene therapy. The articles are available free online at www.liebertpub.com/humTwo review articles...
A gene therapy approach using a protein called CD59, or protectin, shows promise in slowing the signs of age-related macular degeneration (AMD), according to a new in vivo study by researchers at Tufts University School of Medicine. Led by senior author Rajendra Kumar-Singh, PhD, the researchers demonstrated for the first time that CD59 delivered by a gene therapy approach significantly reduced the uncontrolled blood vessel growth and cell death typical of AMD, the most common cause of...
MOUNTAIN VIEW, Calif., April 20, 2011 /PRNewswire/ -- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the release of the iDimerize inducible dimerization systems. Based on the widely used ARGENT(TM) technology developed by ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA), the iDimerize systems enable precise, real-time control of protein-protein interactions using specific cell-permeable chemical ligands, called dimerizers. Any cellular process that can...
Scientists at the Gladstone Institutes have identified networks of genes that play an important role in embryonic-heart development, advancing knowledge of how healthy hearts develop"”and offering clues about how to combat a common birth defect known as congenital heart disease.Congenital heart disease affects nearly 1 out of every 100 babies born worldwide and is the most common cause of death from a birth defect. In the disease, cells in the embryo often fail to get the right instructions...
--Immunotherapy Used in Proof-of-Principle Treatment for Wiskott-Aldrich Syndrome at The Children's Hospital of Philadelphia-- PHILADELPHIA, April 14, 2011 /PRNewswire-USNewswire/ -- In a novel approach that works around the gene defect in Wiskott-Aldrich syndrome, an inherited immune deficiency disorder, researchers used an alternative cell signaling pathway to significantly improve immune function in a 13-year-old boy with the disease. The study, at The Children's Hospital of...
Overcoming the gene silencing barrier opens doors for gene therapy. Lincoln, NE (PRWEB) April 12, 2011 NTC today announced the award of a Small Business Innovation Research (SBIR) Phase II grant award from the National Institute of General Medical Sciences. The award represents a continuation of a Phase I study, which initially demonstrated the feasibility of overcoming transgene silencing, previously, a major barrier to successful gene therapy. In addition to anti-silencing elements,...
GAITHERSBURG, Md., April 11, 2011 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) announced that new research has been published online ahead of print in the journal Gene Therapy, and can be accessed at http://www.nature.com/doifinder/10.1038/gt.2011.33. The article, "Selective atonal gene delivery improves balance function in a mouse model of vestibular disease," describes research conducted by Hinrich Staecker, M.D., Ph.D. and colleagues at the University of Kansas School of Medicine, in...
Thematic program focuses on DNA replication, recombination and repairDNA's role as the master blueprint of the cell means that even small sequence changes can have catastrophic consequences. For this reason, much of our understanding of cancer development comes from studying how cells copy DNA and repair sequence errors -- and how these processes can go wrong.Next week, a thematic program at the American Society for Biochemistry and Molecular Biology's annual meeting at the Experimental...
